Untargeted Metabolomic Analysis Reveals the Mechanism Underlying Swertia mussotii Treatment on Rats With Non‐Alcoholic Fatty Liver Disease Using UPLC‐Q‐TOF/MS
Biomedical Chromatography · 2026-06 · 40 (6)
DOI: 10.1002/bmc.70485 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, online erschienen am 10.05.2026. Verfasst von Minyue Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Analysis, College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China. Hauptthemen laut MEDLINE: Swertia, Non-alcoholic Fatty Liver Disease, Plant Extracts, Metabolome. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Swertia mussotii (SM) is a traditional Tibetan medicine and can effectively treat hepatopathies like non‐alcoholic fatty liver disease (NAFLD). However, the mechanism by which it alleviates NAFLD is largely undetermined. In this study, we determined the efficacy of SM and its associated mechanism in NAFLD with in vivo and in vitro models. NAFLD was induced in mice by administering the high‐fat diet (HFD) and in HepG2 cells via free fatty acid (FFA) stimulation. Treatment with SM significantly reduced body weight, decreased serum lipid levels, alleviated hepatic lipid accumulation, and attenuated liver inflammation and oxidative stress. Integrated untargeted metabolomic analysis was conducted via UPLC‐Q‐TOF/MS, and the results revealed that SM restored dysregulated metabolic pathways, particularly the TCA cycle and amino acid metabolism. Also, SM activated SIRT1/AMPK axis, leading to the phosphorylation of ACC, the downregulation of SREBP‐1c and FASN (the corresponding target), and the upregulation of PPAR‐γ, thereby inhibiting de novo lipogenesis while promoting fatty acid β‐oxidation. In vivo, metabolites may be the active compounds for pharmacological effects. The above results illustrate SM's multi‐target mechanism in treating NAFLD, suggesting its potential as the efficient therapeutic agent and the importance of combining traditional medicine with modern metabolomic studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Analysis, College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
- School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
- Heilongjiang Hospital, Beijing Children's Hospital, Harbin, China.
- School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, M., Sun, J., Tang, S., Li, X., Wang, Y., Xu, Y., Ma, R., Wang, X., Li, X., Wang, Y., Xu, H., Zhang, H., & Wang, Z. (2026). Untargeted Metabolomic Analysis Reveals the Mechanism Underlying Swertia mussotii Treatment on Rats With Non‐Alcoholic Fatty Liver Disease Using UPLC‐Q‐TOF/MS. Biomedical Chromatography, 40(6). https://doi.org/10.1002/bmc.70485
Vancouver
Zhang M, Sun J, Tang S, Li X, Wang Y, Xu Y, et al. Untargeted Metabolomic Analysis Reveals the Mechanism Underlying Swertia mussotii Treatment on Rats With Non‐Alcoholic Fatty Liver Disease Using UPLC‐Q‐TOF/MS. Biomedical Chromatography. 2026;40(6). doi:10.1002/bmc.70485
BibTeX
@article{Zhang2026,
author = {Zhang, Minyue and Sun, Jiakang and Tang, Shuhan and Li, Xintong and Wang, Yige and Xu, Yaqi and Ma, Rong and Wang, Xuexi and Li, Xianna and Wang, Ying and Xu, Hongying and Zhang, Hailong and Wang, Zhigang},
title = {Untargeted Metabolomic Analysis Reveals the Mechanism Underlying Swertia mussotii Treatment on Rats With Non‐Alcoholic Fatty Liver Disease Using UPLC‐Q‐TOF/MS},
journal = {Biomedical Chromatography},
year = {2026},
volume = {40},
number = {6},
doi = {10.1002/bmc.70485}
}
EUVIMED